PRESS RELEASE published on 03/21/2023 at 13:30, 1 year 8 months ago Jaguar Health to Hold Investor Webcast Monday, March 27th at 8:30 AM EDT Regarding Q4 2022 Financials & Corporate Updates
PRESS RELEASE published on 03/15/2023 at 13:30, 1 year 8 months ago Jaguar Health Celebrates U.N. International Day of Forests with Milestone of Providing Income to 20,000+ People Living in Tropical Rainforest Communities
PRESS RELEASE published on 03/13/2023 at 13:30, 1 year 8 months ago Jaguar Health Leveraging AI to Support Patient Access to Mytesi, the Company's FDA-Approved Prescription Drug
PRESS RELEASE published on 03/02/2023 at 14:30, 1 year 8 months ago Jaguar Health to Present at BioTrinity 2023 Conference’s R&D Spotlight on Rare Diseases
PRESS RELEASE published on 02/28/2023 at 14:30, 1 year 8 months ago FDA Grants Orphan Drug Designation to Jaguar Health for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication in the US
PRESS RELEASE published on 02/23/2023 at 14:30, 1 year 9 months ago Jaguar Health Receives Notice of Allowance for U.S. Patent for Lead FDA Approved Drug Crofelemer
PRESS RELEASE published on 02/21/2023 at 14:30, 1 year 9 months ago Jaguar Health Achieves Approximately 75% Enrollment in Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea
PRESS RELEASE published on 02/09/2023 at 14:30, 1 year 9 months ago Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A.
PRESS RELEASE published on 02/08/2023 at 14:30, 1 year 9 months ago Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement
PRESS RELEASE published on 02/01/2023 at 15:45, 1 year 9 months ago Jaguar Health & SynWorld Technologies Mutually Agree to Terminate License and Commercialization Agreement for Canalevia for Treatment of Diarrhea in Dogs in China Given Jaguar’s 2023 Focus on Human Drug Development
Published on 11/25/2024 at 04:00, 3 hours 9 minutes ago Tanzania Safaris Unveils New Luxury Adventure Packages for 2025
Published on 11/22/2024 at 23:55, 2 days 7 hours ago Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 2 days 7 hours ago Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 2 days 8 hours ago Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/24/2024 at 19:16, 11 hours 53 minutes ago EQS-Adhoc: RENK Group AG: Termination of mandate of CEO Susanne Wiegand and appointment of Dr. Alexander Sagel as CEO
Published on 11/24/2024 at 19:07, 12 hours 2 minutes ago EQS-Adhoc: ABO Energy KGaA reduces forecast for the 2024 annual result to EUR 20 to 25 million and confirms market expectation for the 2025 financial year
Published on 11/22/2024 at 18:14, 2 days 12 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 17:53, 2 days 13 hours ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 06:58, 4 days ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 4 days 11 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 4 days 13 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 4 days 13 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
